JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 90 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $132,000 | -68.0% | 19,503 | -60.5% | 0.01% | -76.0% |
| Q4 2021 | $412,000 | +81.5% | 49,384 | +48.2% | 0.02% | +31.6% |
| Q2 2021 | $227,000 | +34.3% | 33,322 | +37.7% | 0.02% | +5.6% |
| Q4 2020 | $169,000 | -71.7% | 24,204 | -64.7% | 0.02% | -48.6% |
| Q4 2019 | $598,000 | +176.9% | 68,528 | +106.4% | 0.04% | +118.8% |
| Q3 2018 | $216,000 | – | 33,197 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |